Product Information
METRONIDAZOLE 375 MG CAPSULE is a generic product labeled by Chartwell RX LLC, priced at $7.3080 per EA under NDC 62135083650. Its NADAC has been published 122 times since Jun 5, 2024.
FDA first approved this application on Jan 29, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Metronidazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
375 mg/1
Manufacturer
Chartwell RX LLCNDC
62135083650
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
1/21/2026
Active Ingredients
METRONIDAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA076522FDA Approved
1/29/2004
TE Code
AB
On Market Since
1/29/2004
Pharmacological Classes
Price Statistics
The NADAC for METRONIDAZOLE 375 MG CAPSULE has been published 122 times since Jun 5, 2024, and over the history we have for it it has risen 13.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.3080 per EA |
|---|---|
| All-time high | $8.0061 (Apr 16, 2025) |
| All-time low | $6.1014 (Jul 17, 2024) |
| 52-week high | $7.7752 |
| 52-week low | $7.3080 |
| Median price | $7.3080 |
| Average price | $7.2828 |
| Largest weekly change | +12.8% (Nov 20, 2024) |
| Weeks tracked | 122 |
| Tracking since | Jun 5, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Metronidazole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metronidazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nitroimidazole Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METRONIDAZOLE 375 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for METRONIDAZOLE 375 MG CAPSULE, manufactured by Chartwell RX LLC, is $7.3080 per EA (NDC 62135083650), effective Sep 30, 2026.
How has the price of METRONIDAZOLE 375 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for METRONIDAZOLE 375 MG CAPSULE has risen 13.9%. It has been tracked across 122 weekly CMS publications since Jun 5, 2024.
What are the highest and lowest recorded NADAC prices for METRONIDAZOLE 375 MG CAPSULE?
Since Jun 5, 2024, the NADAC for METRONIDAZOLE 375 MG CAPSULE has ranged from a low of $6.1014 (Jul 17, 2024) to a high of $8.0061 (Apr 16, 2025), with a median of $7.3080 per EA.
Are there cheaper alternatives to METRONIDAZOLE 375 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of METRONIDAZOLE 375 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METRONIDAZOLE 375 MG CAPSULE?
METRONIDAZOLE 375 MG CAPSULE (NDC 62135083650) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.